ZEFIRO METHANE CORP. (Cboe Canada: ZEFI) (Frankfurt: Y6B) (OTCQB: ZEFIF) (the “Company”, “Zefiro”, or “ZEFI”) is pleased to announce that its ...

During Friday’s Morrow County Chamber of Commerce ribbon-cutting ceremonies, downtown shoppers were delighted with the ...

While the characters on "The Handmaid's Tale" don't get to be glamorous, their portrayals know how to turn up the sparkle on the red carpet.

Since its release in 1985, Margaret Atwood’s The Handmaid’s Tale novel has been banned in several countries, including the United States and Canada.

Gilead To Supply Lenacapavir For People In Low- And Lower-middle-income Countries July 09, 2025 — 08:15 am EDT Written by RTTNews.com for RTTNews -> ...

Gilead Sciences, Inc. (NASDAQ: GILD) is one of the 10 Best Value Stocks to Buy According to Billionaires. The company announced that the US FDA approved Yeztugo ® (lenacapavir), Gilead Sciences ...

By Colin Kellaher Gilead Sciences and Kymera Therapeutics have inked an exclusive cancer-drug option and licensing agreement potentially worth hundreds of million of dollars to Kymera.

Gilead Sciences, Inc. (NASDAQ: GILD) and Kymera Therapeutics, Inc. (NASDAQ: KYMR), today announced that they have entered into an exclusive option and license agreement to accelerate the ...

Gilead’s daily antiviral pills can prevent HIV transmission and slow AIDS. While an HIV vaccine remains the Holy Grail, Gilead’s new long-lasting injection, lenacapavir, is the next best thing.

The injectable HIV prevention treatment Yetzugo, made by Gilead Sciences, has received FDA approval, offering a twice-yearly alternative to daily medications.

A Gilead Sciences drug that protects against HIV infection has won a highly anticipated FDA approval, becoming the first medication for HIV prevention available as a twice-yearly injection.

Pharmaceutical company Gilead Sciences announced Wednesday the Food and Drug Administration (FDA) has approved its six-month, twice-yearly HIV PrEP injection, which was found in trials to be more t… ...